合成了一系列设计为丝氨酸蛋白酶的潜在自杀抑制剂的1,4-双(烷氧基羰基)氮杂环丁烷-2-酮,并针对猪胰弹性蛋白酶(PPE)进行了评估。最活跃的化合物(ķ我〜10μM;可逆抑制剂)装备有分别在位置N1和C4,苯乙苄氧基羰基和侧链,与(小号) -构型。1个反应混合物的1 H NMR光谱分析表明,就氮杂环丁酮和氨基甲酸酯的功能而言,在化学和酶催化的反应中,酯的功能均优先被水解。考虑到三个潜在敏感的羰基官能团和两个立体异构体,从头算来确定在酶口袋模型中达到水解的过渡态结构所需的能垒。
Herein, we report the development of a tailored cobalt catalyst system of Cp*Co(III)(LX) toward intramolecular C-H nitrene insertion of azidoformates to afford cyclic carbamates. The cobalt complexes were easy to prepare and bench-stable, thus offering a convenient reaction protocol. The catalytic reactivity was significantly improved by the electronic tuning of the bidentate LX ligands, and the observed
A series of 1,4-bis(alkoxycarbonyl)azetidin-2-ones, designed as potential suicide-inhibitors of serine proteases, has been synthesized and evaluated against porcine pancreatic elastase (PPE). The most active compound (Ki∼10 μM; reversible inhibitor) was equipped with phenethyloxycarbonyl and benzyloxycarbonyl side-chains at positions N1 and C4, respectively, with the (S)-configuration. 1H NMR spectroscopic
合成了一系列设计为丝氨酸蛋白酶的潜在自杀抑制剂的1,4-双(烷氧基羰基)氮杂环丁烷-2-酮,并针对猪胰弹性蛋白酶(PPE)进行了评估。最活跃的化合物(ķ我〜10μM;可逆抑制剂)装备有分别在位置N1和C4,苯乙苄氧基羰基和侧链,与(小号) -构型。1个反应混合物的1 H NMR光谱分析表明,就氮杂环丁酮和氨基甲酸酯的功能而言,在化学和酶催化的反应中,酯的功能均优先被水解。考虑到三个潜在敏感的羰基官能团和两个立体异构体,从头算来确定在酶口袋模型中达到水解的过渡态结构所需的能垒。
1-Alkoxycarbonyl-3-halogenoazetidin-2-ones as elastase (PPE) inhibitors
A series of 1-alkoxycarbonyl-3-halogenoazetidin-2-ones, designed as potential suicide inhibitors of serine proteases, has been synthesized and evaluated against porcine pancreatic elastase (PPE). All the compounds were transient inhibitors, their activity depending mainly on the nature of the halogen substituent: bromo- and iodo-derivatives are more active (K-i similar to2-22 muM) than 3-chloroazetidinones (K-i similar to20-150 muM). The lipophilicity of the N-1 substituent appeared to exert a slightly positive effect. (C) 2002 Elsevier Science Ltd. All rights reserved.
ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS
申请人:Sun Ying
公开号:US20080125444A1
公开(公告)日:2008-05-29
The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof:
which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.